Loading stock data…
ABT
$90.79-0.54 (-0.59%)
Pre-Market$91.06+0.27 (+0.30%)· Last close Apr 30
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Abbott Laboratories in the Healthcare sector is trading at $90.79. The stock is currently near its 52-week low of $90.29, remaining 24.0% below its 200-day moving average. Technical signals show neutral RSI of 30 and bearish MACD signal, explaining why ABT maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Oversold momentum (RSI 30) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$90.79
Potential Downside
9%
Whystock Fair Value$82.58
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus25 analysts
Buy
Mean target$118.64+30.7%
Range$92.00 – $143.00
Fundamentals
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medica...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$159.35B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
25.69
Beta
Defensive asset. Lower volatility than the S&P 500.
0.78
Div Yield
Strong income play. Yield provides a meaningful total return floor.
275.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
26.82%
Volume
Today's trading volume
14.63M
Recent News
Abbott Laboratories (ABT) Receives FDA Clearance and CE Mark for Next-Generation Ultreon™ 3.0 Software
Abbott Laboratories (NYSE:ABT) is one of the best medical device stocks to invest in right now. Abbott Laboratories (NYSE:ABT) announced on April 28 that it received the U.S. Food and Drug Administration (FDA) clearance and CE Mark for its next-generation Ultreon™ 3.0 Software. Management stated that the milestone marks a considerable step forward for the […]
Dexcom reaffirms full-year forecast after topping quarterly estimates
April 30 (Reuters) - Medical device maker Dexcom on Thursday reiterated its full-year revenue forecast after beating Wall Street estimates for quarterly results, helped by strong demand for its
How Investors Are Reacting To Abbott (ABT) Gaining FDA, CE Clearance For AI-Guided Ultreon 3.0
Earlier this week, Abbott received U.S. FDA clearance and CE Mark for Ultreon 3.0, an AI-powered optical coherence tomography platform that integrates high‑resolution coronary imaging with automated insights to guide stent sizing and placement in complex percutaneous coronary interventions. This positions Abbott at the forefront of AI-guided cardiovascular care, potentially making OCT a more intuitive, workflow-friendly tool for treating challenging coronary disease cases. Next, we’ll...
Jim Cramer Believes “BillionToOne’s a Winner”
BillionToOne, Inc. (NASDAQ:BLLN) was among the stocks Jim Cramer covered on Mad Money as he discussed the wave of IPOs being the market’s possible biggest threat. When a caller inquired about the stock, Cramer said: We looked into BillionToOne. We think it’s a really good diagnostic company. Now, the diagnostic companies themselves have been going […]
Augment makes first move into $8 trillion distribution sector
The AI productivity platform has acquired stealth startup Merlin, a stealth AI company focused on wholesale distribution The post Augment makes first move into $8 trillion distribution sector appeared first on FreightWaves.